AstraZeneca Tries Plan B For Dato-DXd After Regulator Feedback

 
• By Andrew McConaghie
  
AZ is looking for a narrower indication for its lung cancer candidate after withdrawing its initial FDA application. (Shutterstock)

More from Review Pathways

More from Pathways & Standards